Tardive Dyskinesia Market to Grow Rapidly at a CAGR of 8.1% During the Forecast Period (2026-2036) | DelveInsight

DelveInsight projects the tardive dyskinesia (TD) market to grow through 2036, supported by improved diagnosis and new therapy launches. The market size was $4.4B in 2025 across the 7MM (~1.7M prevalent cases), with the U.S. comprising ~98% of that market. Growth catalysts include emerging Phase II/IIb assets such as Neurocrine’s NBI-1065890 and SOM Biotech’s SOM3355, alongside broader uptake of VMAT2 inhibitors (e.g., INGREZZA, AUSTEDO XR) despite persistent unmet needs around tolerability and limited mechanistic diversity.

Analysis

This is more confirmation than revelation: the investable edge is not the size of the addressed market, but the durability of the incumbent franchise while diagnosis rates slowly rise. That structurally favors NBIX because it already monetizes physician familiarity, payer pathways, and persistence; in a specialty CNS market, switching costs and prescriber inertia matter more than pipeline breadth. The market may be underestimating how much of the incremental growth can be captured without a true mechanism shift, which is why the near-term earnings sensitivity still sits with the incumbent rather than the speculative pipeline names.

The second-order issue is that better recognition expands the treatable pool only if psychiatrists actually screen and document abnormal movements; that is a multi-quarter to multi-year adoption curve, not a sudden volume inflection. As a result, the immediate catalyst is not a market-size report, but any evidence that treatment persistence, refill behavior, or managed-care access improves for VMAT2s. If reimbursement tightens or if safety concerns in elderly/comorbid patients re-emerge, the growth thesis gets pushed out even if prevalence continues to climb.

For competitors, the report implicitly raises the bar for ACAD and SER: early-stage assets need differentiated tolerability or dosing convenience to win share from a cash-generative incumbent, otherwise they are just call options on a long-dated category expansion. The contrarian view is that the pipeline is still too thin for true class disruption, so the most likely outcome is share defense by NBIX and incremental cannibalization of lower-quality use cases, not a wholesale market reset. That keeps valuation support on NBIX, but limits upside unless the next Phase II data show a cleaner safety/efficacy profile than the current class.

Key Decisions for Investors

• Long NBIX on any post-release weakness; 3-12 month thesis is share defense plus continued category expansion, with downside falsified if Phase II NBI-1065890 or commercial persistence data disappoint.
• Relative value: long NBIX / short ACAD into the next 6-9 months. NBIX has monetizable cash flow and de-risked execution; ACAD is mostly binary pipeline optionality until first-in-human data, so it is vulnerable if risk appetite cools.
• Treat SER as a watchlist name, not a buy: the market will likely capitalize it as a long-dated platform story until clinical proof emerges. Consider only on a steep pullback after any speculative run-up.
• Set an alert on NBIX if payer commentary or new prescription trends show deceleration for VMAT2s; that would invalidate the thesis faster than any macro read-through.
• If seeking options exposure, prefer NBIX call spreads into a Phase II catalyst rather than outright ACAD/ SER calls; the better risk/reward is on a company with existing revenue sensitivity, not a pre-approval pipeline story.